bioRxivPathology
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets
M. C. Baldauf, M. F. Orth, M. Dallmayer, A. Marchetto, J. S. Gerke, R. Alba Rubio, M. M. Kiran, J. Musa, M. M. L. Knott, S. Ohmura, J. Li, N. Akpolat, A. N. Akatli, O. Ozen, U. Dirksen, W. Hartmann, E. de Alava, D. Baumhoer, G. Sannino, T. Kirchner, T. G. P. Grunewald
Abstract
Ewing sarcoma is an undifferentiated bone-associated cancer. Although molecular detection of pathognomonic EWSR1-ETS fusions such as EWSR1-FLI1 enables definitive diagnosis, substantial confusion can arise if molecular diagnostics are unavailable. Diagnosis based solely on the conventional immunohistochemical marker CD99 is unreliable due to its abundant expression in morphological mimics. This study aimed to identify novel diagnostic immunohistochemical markers for Ewing sarcoma.\n\nWe analyzed 768 expression microarrays representing 21 tumor entities including Ewing-like sarcomas to nominate candidate biomarkers. These candidates were validated by immunohistochemistry (IHC) in a tissue microarray (TMA) comprising 174 samples. Microarray, chromatin immunoprecipitation and sequencing (ChIP-Seq) data, and reporter assays were employed to analyze their EWSR1-FLI1-dependency.\n\nOur comparative expression analyses revealed that ATP1A1, BCL11B, and GLG1 constitute specific markers for Ewing sarcoma. Analysis of ChIP-Seq and microarray datasets showed that their expression is EWSR1-FLI1-dependent. This outcome corresponded to EWSR1-FLI1-binding to proximal super-enhancers, which showed high activity in reporter assays. Consistently, high ATP1A1, BCL11B, and GLG1 expressions were detected by IHC. Automated cut-off-finding and combination-testing in the TMA demonstrated that detection of high BCL11B and/or GLG1 expression is sufficient to reach 96% specificity for Ewing sarcoma. While 88% of tested Ewing-like sarcomas displayed strong CD99-immunoreactivity, none displayed combined high expression of BCL11B and GLG1.\n\nCollectively, we provide evidence that ATP1A1, BCL11B, and GLG1 are EWSR1-FLI1 targets, of which BCL11B and GLG1 offer a fast, simple and cost-efficient way to diagnose Ewing sarcoma by IHC. We anticipate that these markers will significantly reduce the number of misdiagnosed patients, and thus improve patient care.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1
Q. Deng, R. Natesan, … i. a. asangani·bioRxiv·Feb 22, 2021
- An EWS::FLI1 monoclonal antibody with multimodal utility and specificity for FLI1
Saravana P. Selvanathan, Jeffrey A. Toretsky·bioRxiv·Nov 13, 2023
- Osteosarcoma with apparent Ewing sarcoma gene rearrangement
Melissa Mathias, Alexander Chou, … Alex Kentsis·Journal of Pediatric Hematology/OncologyPeer-reviewed·Jul 1, 2016
- CK2 inhibitor CX-4945 targets EWS-FLI1 signaling network and shows therapeutic efficacy in metastatic mouse models of Ewing Sarcoma
Muhammad Daniyal, Rajesh Rajaiah, … Chandrika Gowda Behura·bioRxiv·Sep 24, 2025
- Radiological Patterns in Maxillofacial Ewing Sarcoma: A systematic review with pooled patient-level descriptive analysis
Ajo Babu George, Shishir Maharana, … Sonam Khurana·bioRxiv·Aug 17, 2026
- EWS-FLI-1 creates a cell surface microenvironment conducive to IGF signaling by inducing pappalysin-1.
P. Jayabal, P. J. Houghton, Y. Shiio·bioRxiv·Sep 28, 2017